Email this article A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
- Authors: Alekseev B.Y.1, Kaprin A.D.2, Nyushko K.M.3
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute Department of Urology with a Course of Oncology, Russian Peoples’ Friendship University
- Department of Urology with a Course of Oncology, Russian Peoples’ Friendship University City Clinical Hospital Twenty, Moscow
- P.A. Herzen Moscow Oncology Research Institute
- Issue: Vol 7, No 2 (2011)
- Pages: 84-87
- Section: PROSTATE CANCER
- Published: 30.06.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/164
- DOI: https://doi.org/10.17650/1726-9776-2011-7-2-84-87
- ID: 164
Cite item
Full Text
Abstract
Prostate cancer (PC) is one of the most pressing problems of urologic cancer due to higher morbidity from this pathology worldwide. Treatment policy in PC patients is determined by the extent of a cancer process. Radical therapy for metastatic PC is impossible, hence this patient group is considered eligible for palliative hormonal or chemotherapy. To choose the optimal treatment for patients with hormone-refractory PS (HRPS) is an intricate problem regarding particularly patients with asymptomatic HRPS and those with progressive cancer after chemotherapy with docetaxel. In this instance, the treatment policy is a matter of discussion and is not well defined. The paper considers the use of somatostatin analogues as an alternative to drug therapy for patients with HRPS. Octreotide is one of the most popular drugs of this group. The agent may be used to treat patients with HRPS both before and after systemic cytotoxic therapy. Octreotide therapy is effective and safe; its side effects are minimal and it is well tolerated in patients.
About the authors
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research InstituteDepartment of Urology with a Course of Oncology, Russian Peoples’ Friendship University
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
A. D. Kaprin
Department of Urology with a Course of Oncology, Russian Peoples’ Friendship UniversityCity Clinical Hospital Twenty, Moscow
Email: byalekseev@mail.ru
Russian Federation
K. M. Nyushko
P.A. Herzen Moscow Oncology Research Institute
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
